QIAGEN N.V.
QGENQIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer (CEO).
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
QGEN Earnings Report
EPS Est: $0.60 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is QIAGEN N.V.'s next FDA catalyst?→
QIAGEN N.V.'s (QGEN) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track QGEN biotech catalysts?→
Add QGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow QIAGEN N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.